Prosecution Insights
Last updated: November 11, 2026
Application No. 18/718,186

NOVEL PEPTIDE DERIVATIVE DERIVED FROM ADIPONECTIN AND USE THEREOF

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Jun 10, 2024
Priority
Dec 10, 2021 — RE 10-2021-0176940 +2 more
Examiner
BRADLEY, CHRISTINA
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Daegu-Gyeongbuk Medical Innovation Foundation
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
3m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
651 granted / 1040 resolved
+2.6% vs TC avg
Strong +33% interview lift
Without
With
+33.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
62 currently pending
Career history
1111
Total Applications
across all art units

Statute-Specific Performance

§101
6.0%
-34.0% vs TC avg
§103
28.9%
-11.1% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1040 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of the species Chemical Formula 1-31 in the reply filed on September 11, 2026, is acknowledged. The traversal is on the ground(s) that the species of claim 5 share a distinctive structural core and function. This is not found persuasive because the compounds, their structural core, and their function are known in the prior art (see anticipation and obviousness rejections below). The requirement is still deemed proper and is therefore made FINAL. Claim 4 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Elected species Chemical Formula 1-31 does not have a C15-C20 heterocycloalkene group linking R3 and R7. The elected species was searched and prior art was found. Therefore, the search was not extended further in accordance with MPEP § 803.02. Nucleotide and/or Amino Acid Sequence Disclosures Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: Specific deficiency - Sequences appearing in the specification are not identified by sequence identifiers (i.e., “SEQ ID NO:X” or the like) in accordance with 37 CFR 1.831(c). The amino acid sequences in claim 5 must include a sequence identifier every time they appear in the claims and specification, including when depicted as a chemical structure. Required response – Applicant must provide: A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers, consisting of: • A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); • A copy of the amended specification without markings (clean version); and • A statement that the substitute specification contains no new matter. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 8-9 and 12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to pharmaceutical and cosmetic compositions for preventing, treating, or alleviating inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, cancer, aging, sensitive skin, wrinkles and moisturization comprising peptide derivatives of Chemical Formula 1. The number of peptide derivatives meeting the structural requirements of Chemical Formula 1 is enormous. However, only those sequences meeting the structural and functional requirements of the genus are encompassed by the claim. Therefore, the claims are limited to peptides that meet the structural requirements of Chemical Formula 1 that are also able to prevent, treat, or alleviate inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, cancer, aging, sensitive skin, wrinkles and moisturization. The instant specification includes a limited reduction to practice. Three species, Chemical Formula 1-8 (GDYYF-NH2), 1-18 (DYYF), and 1-31 (GLYYF-NH2), were tested for their effect on hair growth in a mouse model (FIG. 18, Example 9), skin aging in a mouse model (FIG. 19, Example 9), neutral fat removal in a mouse adipocyte cell line (FIG. 20), and skin sensitivity in a human myocyte cell line (FIG. 21). These species are not representative of the full scope of the structural genus which includes: alkylamide and imidazoylmethyl groups as well as alkylcarboxyl and acyclic alkyl groups of other carbon numbers at position R4; unsubstituted benzyl groups, benzyl groups with other substitutions, and indolylmethyl groups at position R5 and R6, alkylamino groups, unsubstituted benzyl groups, benzyl groups with other substitutions, and indolylmethyl groups at position R5 and R6, N-terminal modifications, and Cyclization via R3 and R7. These assays and animal models are not representative of the full scope of the claimed intended use which also includes all inflammatory skin diseases, wounds, fibrosis, all metabolic diseases, all cancers, all aging effects, and all types of skin sensitivities. Therefore, the instant specification has failed to meet the written description requirement by actual reduction to practice of a representative number of species alone. The claimed peptides are derived from adiponectin. The specification presents an AMPL phosphorylation activity in vitro assay to assess the activity of a large number of synthesized peptide derivatives (Example 2, FIGs. 1-10). However, many of the tested species fail to exhibit statistically significant activity compared to vehicle. The specification does not provide an explanation of the range of observed activities nor does it describe a general correlation between structure and function for the claimed genus. As a result, it is impossible to predict, based on the specification, how changing any position will affect the claimed functions. Given this high degree of unpredictability, the broad scope of the claims with respect to structure and intended use, and the limited reduction to practice, one of ordinary skill in the art would not know which of the countless peptides that meet the structural requirements of the claims would also be able to perform the complicated claimed functions. The specification does not make clear which peptides are in the genus and which are not because it does not describe the physical basis for the claimed activity. In other words, the specification does not describe which peptides to make. For these reasons, the skilled artisan would not reasonably conclude that the inventor(s), at the time the application was filed, had possession of the full scope of the claimed invention. Claims 1-3, 5-6, 8-9, and 12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for using Formula 1-8 (GDYYF-NH2), 1-18 (DYYF), and 1-31 (GLYYF-NH2) to promote hair growth, increase collagen expression, inhibit neutral fat accumulation in adipocytes, and reduce the expression of a CGRP pain neurotransmitter in myocytes does not reasonably provide enablement for other uses with these peptides or the use of any other claimed peptides for any purpose. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. To comply with the enablement requirements of 35 U.S.C. §112, first paragraph, a specification must adequately teach how to make and how to use a claimed invention throughout its scope, without undue experimentation. Plant Genetic Systems N.V. v. DeKalb Genetics Corp., 315 F.3d 1335, 1339, 65 USPQ2d 1452, 1455 (Fed. Cir. 2003). There are a variety of factors which may be considered in determining whether a disclosure would require undue experimentation. These factors include (In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)): The nature of the invention and the breadth of the claims The claims are drawn to compositions for preventing, treating, or alleviating inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, cancer, aging, sensitive skin, wrinkles and moisturization comprising peptide derivatives of Chemical Formula 1, which according to the specification are derived from adiponectin. The number of peptide derivatives meeting the structural requirements of Chemical Formula 1 is enormous. However, only those sequences meeting the structural and functional requirements of the genus are encompassed by the claim. Therefore, the claims are limited to peptides that meet the structural requirements of Chemical Formula 1 that are also able to prevent, treat, or alleviate inflammatory skin diseases, wounds, hair loss, fibrosis, metabolic diseases, cancer, aging, sensitive skin, wrinkles and moisturization. The presence or absence of working examples The instant specification includes a limited reduction to practice. Three species, Chemical Formula 1-8 (GDYYF-NH2), 1-18 (DYYF), and 1-31 (GLYYF-NH2), were tested for their effect on hair growth in a mouse model (FIG. 18, Example 9), skin aging in a mouse model (FIG. 19, Example 9), neutral fat removal in a mouse adipocyte cell line (FIG. 20), and skin sensitivity in a human myocyte cell line (FIG. 21). These species are not representative of the full scope of the structural genus which includes: alkylamide and imidazoylmethyl groups as well as alkylcarboxyl and acyclic alkyl groups of other carbon numbers at position R4; unsubstituted benzyl groups, benzyl groups with other substitutions, and indolylmethyl groups at position R5 and R6, alkylamino groups, unsubstituted benzyl groups, benzyl groups with other substitutions, and indolylmethyl groups at position R5 and R6, N-terminal modifications, and Cyclization via R3 and R7. These assays and animal models are not representative of the full scope of the claimed intended use which also includes all inflammatory skin diseases, wounds, fibrosis, all metabolic diseases, all cancers, all aging effects, and all types of skin sensitivities. The amount of direction or guidance presented The claimed peptides are derived from adiponectin. The specification presents an AMPL phosphorylation activity in vitro assay to assess the activity of a large number of synthesized peptide derivatives (Example 2, FIGs. 1-10). However, many of the tested species fail to exhibit statistically significant activity compared to vehicle. The specification does not provide an explanation of the range of observed activities nor does it describe a general correlation between structure and function for the claimed genus. As a result, it is impossible to predict, based on the specification, how changing any position will affect the claimed functions. The state of the prior art, the relative skill of those in the art, and the predictability or unpredictability of the art Chung et al. (WO 2020/050428 A1; published December 3, 2020, citations refer to English language equivalent US 11,771,636 B2) teach a peptide having the amino acid sequence Gly-Leu-Tyr-Tyr-Phe (SEQ ID NO: 16) (col 2, lns 60-65). The prior art peptide corresponds to a peptide derivative of Chemical Formula 1 wherein R1 is NH2, R2 is OH, R3 is H, n is 1, R4 is C4 alkyl, R5 is benzyl substituted with a hydroxyl, R6 is benzyl substituted with a hydroxyl, R7 is benzyl, and R8, R9, and R10 are H. Chung et al. teaches that the peptide is intended for use in methods of promoting hair growth (col 2, ln 60- col 3, ln 25) and inhibiting hair loss (col 4, lns 40-50). To that end, Chung et al. teaches both pharmaceutical (col 6) and cosmetic (col 5) compositions comprising the peptide as an active ingredient. Chung et al. (WO 2020.0540429 A1) and Chung et al. (WO 2020/050427 A1) teach that the same peptide can be used for treating sensitive skin and to prevent skin aging or wrinkles. Monks et al. (Complex interaction of adiponectin-mediated pathways on cancer treatment: a novel therapeutic target. J Cancer Metastasis Treat 2019;5:24) confirm that adiponectin is a target for many obesity-related cancers. However, as of the time the instant application was filed, no compounds targeting adiponectin, including peptides derived from adiponectin, have been approved for use. Furthermore, Monks et al. underscore the complexity and unpredictability of the field. The quantity of experimentation necessary The scope of the claimed compositions and therapeutic indications are extremely broad relative to the narrow reduction to practice in the specification. That fact combined with the level of unpredictability and complexity in the art, the relative skill in the art, and the lack of specific guidance in the specification, poses an undue burden of experimentation on one of ordinary skill in the art seeking to practice the claimed methods. The specification is an invitation to undertake a research program to identify additional compositions that could be used to carry out different embodiments of the claims. As such, the specification fails to meet the enablement provision of 35 U.S.C. 112(a). Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 5-6, 8-9, and 12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the parenthetical phrase "(wherein m is an integer of 1 to 5)" renders the claim indefinite because it is unclear whether the limitation in parentheses is part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 1, in the definition of R5 and R6, the indefinite language is: “wherein the benzyl group is unsubstituted or at least one selected from the group consisting of a hydroxyl group….”. The language is indefinite because it is not clear how a benzyl group can be a hydroxyl group or the other options listed in the Markush group. As a result, the definition of variables R5 and R6 and the structure of Chemical Formula 1 are undefined. Regarding claim 1, in the definition of R7, the indefinite language is: “wherein the benzyl group is unsubstituted or at least one selected from the group consisting of a hydroxyl group….”. The language is indefinite because it is not clear how a benzyl group can be a hydroxyl group or the other options listed in the Markush group. As a result, the definition of variables R5 and R6 and the structure of Chemical Formula 1 are undefined. In claim 1, the indefinite language is “R3 and R7 are linked to each other to form…”. The language is indefinite at least because R3, which is defined as H, cannot link to R7. In claim 1, the limitation “when n is 0, R4 is a C2-C6 alkylcarboxyl group, and R5, R6, and R7 are benzyl groups,” is inconsistent with the limitation “however, R1 is NH2, R2 is OH, R3 is hydrogen, R4 is an isobutyl group, R5 and R6 are both hydroxybenzyl groups, R7 is an unsubstituted benzyl group, and R8, R9, and R10 are all hydrogen, except for the case where n is 1” because both limitations describe the structural requirements for when n is 01. The first clause “when n is 0…” requires that R4 is a C2-C6 alkylcarboxyl group whereas the second clause “however” requires that R4 is an isobutyl group. Both cannot be true. In addition, the first clause “when n is 0…” describes a broader limitation than the second clause “however…”. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation “when n is 0,… R5, R6, and R7 are benzyl groups”, and the claim also recites “however… R5 and R6 are both hydroxybenzyl groups, R7 is an unsubstituted benzyl group” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Furthermore, “however, R1 is NH2, R2 is OH, R3 is hydrogen, R4 is an isobutyl group, R5 and R6 are both hydroxybenzyl groups, R7 is an unsubstituted benzyl group, and R8, R9, and R10 are all hydrogen, except for the case where n is 1” is indefinite because this clause describes the structural requirements for when n is 01, which means that R3 should be absent not hydrogen. Dependent claims 2-6, 8-9, and 12 fail to remedy these issues and are likewise rejected. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 5 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 5, depends from claim 1, which requires “R3 and R7 are linked to each other to form…”. Therefore, the peptide derivatives recited in claim 1 that are linear fail to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 6, 8-9, and 12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chung et al. (WO 2020/050428 A1; published December 3, 2020, citations refer to English language equivalent US 11,771,636 B2). Chung et al. teach a peptide having the amino acid sequence Gly-Leu-Tyr-Tyr-Phe (SEQ ID NO: 16) (col 2, lns 60-65). The prior art peptide corresponds to a peptide derivative of Chemical Formula 1 wherein R1 is NH2, R2 is OH, R3 is H, n is 1, R4 is C4 alkyl, R5 is benzyl substituted with a hydroxyl, R6 is benzyl substituted with a hydroxyl, R7 is benzyl, and R8, R9, and R10 are H. Therefore, claim 1 is anticipated by Chung et al. With respect to claim 2, R4 is CH2CH(CH3)2. With respect to claim 3, R5 and R6 are PNG media_image1.png 70 82 media_image1.png Greyscale . With respect to claim 6, the prior art peptide is SEQ ID NO: 15. With respect to claims 8-9 and 12, Chung et al. teaches that the peptide is intended for use in methods of promoting hair growth (col 2, ln 60- col 3, ln 25) and inhibiting hair loss (col 4, lns 40-50). To that end, Chung et al. teaches both pharmaceutical (col 6) and cosmetic (col 5) compositions comprising the peptide as an active ingredient. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-3, 5-6, 8-9, and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Chung et al. (WO 2020/050428 A1; published December 3, 2020, citations refer to English language equivalent US 11,771,636 B2) in view of Henninot et al. (The Current State of Peptide Drug Discovery: Back to the Future?. J. Med. Chem. 22 February 2018; 61 (4): 1382–1414). Chung et al. teach a peptide having the amino acid sequence Gly-Leu-Tyr-Tyr-Phe (SEQ ID NO: 16) (col 2, lns 60-65). The prior art peptide corresponds to a peptide derivative of Chemical Formula 1 wherein R1 is NH2, R2 is OH, R3 is H, n is 1, R4 is C4 alkyl, R5 is benzyl substituted with a hydroxyl, R6 is benzyl substituted with a hydroxyl, R7 is benzyl, and R8, R9, and R10 are H. Chung et al. teaches that the peptide is intended for use in methods of promoting hair growth (col 2, ln 60- col 3, ln 25) and inhibiting hair loss (col 4, lns 40-50). To that end, Chung et al. teaches both pharmaceutical (col 6) and cosmetic (col 5) compositions comprising the peptide as an active ingredient. Chung et al. do not teach that the peptide GLYYF is amidated at the C-terminus. Henninot et al. teach that C-terminal amidation of pharmaceutical peptides improves stability and prevents degradation by inhibiting the activity of carboxypeptidases (Section 6.3). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the GLYFF peptide of Chung et al. by C-terminal amidation as taught by Henninot et al. The resulting peptide would be identical to elected species Chemical Formula 1-31. The rationale for obviousness is some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention (MPEP § 2143.01(G)). One of ordinary skill in the art would have been motivated to make the modification in order to improve the stability of the peptide to degradation by carboxypeptidases because Chung et al. teach that the peptide has therapeutic and cosmetic utility. There would have been a reasonable expectation of success given that Henninot et al. teach that C-terminal amidation of peptides is routine and widely used in the art (Section 6.3). Therefore, claim 1 is prima facie obvious over the cited art. With respect to claim 2, R4 is CH2CH(CH3)2. With respect to claim 3, R5 and R6 are PNG media_image1.png 70 82 media_image1.png Greyscale . With respect to claim 5, the peptide is Chemical Formula 1-31. With respect to claim 6, the prior art peptide is SEQ ID NO: 15. With respect to claims 8-9 and 12, Chung et al. teaches that the peptide is intended for use in methods of promoting hair growth (col 2, ln 60- col 3, ln 25) and inhibiting hair loss (col 4, lns 40-50). To that end, Chung et al. teaches both pharmaceutical (col 6) and cosmetic (col 5) compositions comprising the peptide as an active ingredient. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-3, 5-6, 8-9, and 12 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 and 9-20 of copending Application No. 18/024,819 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because reference claims anticipate the instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Reference claim 1 recites a peptide having the amino acid sequence Gly-Leu-Tyr-Tyr-Phe (SEQ ID NO: 2), with an amino group at the C-terminus (i.e. Gly-Leu-Tyr-Tyr-Phe-NH2). The reference peptide is identical to the elected species and corresponds to a peptide derivative of Chemical Formula 1 wherein R1 is NH2, R2 is NH2, R3 is H, n is 1, R4 is C4 alkyl, R5 is benzyl substituted with a hydroxyl, R6 is benzyl substituted with a hydroxyl, R7 is benzyl, and R8, R9, and R10 are H. Therefore, claim 1 is anticipated. With respect to claim 2, R4 is CH2CH(CH3)2. With respect to claim 3, R5 and R6 are PNG media_image1.png 70 82 media_image1.png Greyscale . With respect to claim 5, the reference peptide is the same as Chemical Formula 1-31. With respect to claim 6, the reference peptide is a modified peptide of SEQ ID NO: 15. With respect to claim 8, reference claim 15 recites a pharmaceutical composition comprising the peptide for treating a metabolic disease. With respect to claim 9, reference claim 7 recites a cosmetic composition comprising the peptide for improving at least one of a skin wrinkle, sensitive skin, dermatitis, and a hair growth, the method comprising administering the pharmaceutical composition. With respect to claim 12, reference claim 7 recites a method for improving at least one of a skin wrinkle, sensitive skin, dermatitis, and a hair growth, the method comprising administering the cosmetic composition. Reference claim 15 recites a pharmaceutical composition comprising the peptide for treating a metabolic disease. Claims 1-3, 6, 8-9, and 12 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3 of US 11,771,636. Although the claims at issue are not identical, they are not patentably distinct from each other because reference claims anticipate the instant claims. Patented claim 1 recites a peptide having the amino acid sequence Gly-Leu-Tyr-Tyr-Phe (SEQ ID NO: 16). The patented corresponds to a peptide derivative of Chemical Formula 1 wherein R1 is NH2, R2 is OH, R3 is H, n is 1, R4 is C4 alkyl, R5 is benzyl substituted with a hydroxyl, R6 is benzyl substituted with a hydroxyl, R7 is benzyl, and R8, R9, and R10 are H. Therefore, claim 1 is anticipated. With respect to claim 2, R4 is CH2CH(CH3)2. With respect to claim 3, R5 and R6 are PNG media_image1.png 70 82 media_image1.png Greyscale . With respect to claim 6, the patented peptide is SEQ ID NO: 15. With respect to claim 8, patented claim 1 recites a cosmetic composition comprising the peptide. The composition is intended for use in promoting hair growth (col 2, lns 60-65). Therefore, the claimed composition is also suitable for use as a pharmaceutical composition for promoting hair growth. With respect to claim 9, patented claim 1 recites a cosmetic composition comprising the peptide. The composition is intended for use in promoting hair growth (col 2, lns 60-65). With respect to claim 12, a claim to a method of using a composition is not patentably distinct from an earlier claim to the identical composition in a patent disclosing the identical use (Sun Pharmaceutical. Industries, Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010)). In the instant case, the reference patent discloses a method of using the composition to promote hair growth (col 2, lns 60-65). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA M MARCHETTI BRADLEY whose telephone number is (571)272-9044. The examiner can normally be reached Monday-Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G Garyu can be reached at (571) 270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHRISTINA M MARCHETTI BRADLEY Primary Examiner Art Unit 1654 /CHRISTINA M MARCHETTI BRADLEY/Primary Examiner, Art Unit 1654 1 The variable n is only 0 or 1 meaning that “except for the case when n is 1” refers to the case when n is 0.
Read full office action

Prosecution Timeline

Jun 10, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779017
EXENATIDE ANALOG
4y 7m to grant Granted Nov 03, 2026
Patent 12780893
CONFORMATIONALLY CONSTRAINED GLUCAGON ANALOGUES AND THEIR USE IN GLUCAGON-SINGLE CHAIN INSULIN FUSION PROTEINS
3y 2m to grant Granted Nov 03, 2026
Patent 12779012
KEAP1/NRF2 PROTEIN-LIKE POLYMERS
3y 1m to grant Granted Nov 03, 2026
Patent 12760067
PEPTIDES FOR USE IN SKIN AND HAIR PIGMENTATION
3y 5m to grant Granted Oct 13, 2026
Patent 12758482
COMPOSITIONS AND METHODS RELATING TO STIMULATION OF HYALURONIC ACID
3y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
96%
With Interview (+33.3%)
2y 8m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1040 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month